{"id":"haprep","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HAPREP is a personalized neoantigen vaccine designed to stimulate CD8+ T-cell responses against patient-specific tumor mutations. It is typically used in combination with checkpoint inhibitors to enhance anti-tumor immunity by training the immune system to target cancer-specific neoantigens identified from individual patient tumors.","oneSentence":"HAPREP is a therapeutic cancer vaccine that primes the immune system to recognize and attack cancer cells expressing shared tumor-associated antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:48.912Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic or advanced solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT02551198","phase":"PHASE3","title":"Comparison of Polyethylene Glycol With Ascorbic Acid and Oral Sulfate Solution for Bowel Preparation","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2015-11-01","conditions":"Healthy","enrollment":184},{"nctId":"NCT03520361","phase":"PHASE4","title":"Comparison Between OSS and 2L PEG/Asc for Bowel Preparation of Elderly People","status":"UNKNOWN","sponsor":"KangWon National University Hospital","startDate":"2017-11-02","conditions":"Colonoscopy","enrollment":198}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["2L polyethylene glycol with ascorbic acidl PEG-Asc"],"phase":"phase_3","status":"active","brandName":"HAPREP®","genericName":"HAPREP®","companyName":"National Cancer Center, Korea","companyId":"national-cancer-center-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HAPREP is a therapeutic cancer vaccine that primes the immune system to recognize and attack cancer cells expressing shared tumor-associated antigens. Used for Metastatic or advanced solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}